Rabies

Crucell announces start of rabies antibody product clinical trial

Published in Vaccine Weekly, January 17th, 2007

Dutch biotechnology company Crucell N.V. (CRXL; CRX) announced that the rabies monoclonal antibody product it is currently developing has entered a Phase I clinical study in the United States.

Crucell has developed a human monoclonal antibody product, a combination of two monoclonal antibodies for the post-exposure prophylaxis (PEP) of rabies, using its MAbstract and PER.C6 technology. The preclinical evaluation of the antibody product was performed in collaboration with the Rabies Program of the Centers for Disease Control and Prevention (CDC) in Atlanta.

The Crucell-funded U.S. clinical trial will be a randomized, double-blind, placebo controlled...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry